Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Accumulated Expenses (2017 - 2025)

Adma Biologics' Accumulated Expenses history spans 13 years, with the latest figure at $172000.0 for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 94.84% year-over-year to $172000.0; the TTM value through Dec 2025 reached $172000.0, down 94.84%, while the annual FY2025 figure was $172000.0, 94.84% down from the prior year.
  • Accumulated Expenses reached $172000.0 in Q4 2025 per ADMA's latest filing, up from $105000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $28.7 million in Q2 2023 to a low of $105000.0 in Q3 2025.
  • Average Accumulated Expenses over 5 years is $6.8 million, with a median of $3.4 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: surged 1372.8% in 2023, then plummeted 96.95% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $1.2 million in 2021, then soared by 250.28% to $4.2 million in 2022, then crashed by 86.98% to $546000.0 in 2023, then skyrocketed by 510.26% to $3.3 million in 2024, then crashed by 94.84% to $172000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Accumulated Expenses are $172000.0 (Q4 2025), $105000.0 (Q3 2025), and $3.4 million (Q2 2025).